Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma

Leukemia and Lymphoma

Volumn 43, Issue 2, 2002, Pages 401-406

  Dmoszynska, Anna ^a   Bojarska Junak, Agnieszka ^a   Domanski, Damian ^a   Rolinski, Jacek ^a   Hus, Marek ^a   Soroka Wojtaszko, Maria ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Mutliple myeloma; Proangiogenic cytokines; Thalidomide; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 6; THALIDOMIDE; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW EXAMINATION; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TABLET FORMULATION;

EID: 0036195061     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190290006224     Document Type: Article

References (26)

1. "Management of multiple myeloma today"
2. "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia"
3. "Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia"
4. "Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes"
5. Thalidomide (T) in the Management of Multiple Myeloma (MM): The Arkansas Experience in >300 Patients with single agent and combination chemotherapy
6. "Serum levels of interleukin 6-a potent myeloma growth factor, as a reflect of disease severity in plasma cell dyscrasia"
7. "Thalidomide is an inhibitor of angiogenesis"
8. "Thalidomide-a new possibilities of treatment for patients with multiple myeloma"
9. "Angiogenesis and metastasis"
10. "Vascular endothelial growth factor"
11. Angiogenesis
12. "Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis"
13. "Elevated levels of angiogenic cytokines in the plasma of cancer patients"
14. "Thalidomide costimulates human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset"
15. "Concomitant elevation of serum VEGF and bFGF i strongly associated with poor outcome in non-Hodgkin's lymphoma"
16. "Tumor necrosis factor is a survival and proliferation factor for human myeloma cells"
17. "Basic fibroblast growth factor induces angiogenesis in vitro"
18. "High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma"
19. "Thalidomide - A revival story"
20. "A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma"
21. "Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma"
22. "Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase 2 secretion parallel progression of human multiple myeloma"
23. "Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma. Abstracts of 42th ASH Meeting"
24. "Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma"
25. "Bone marrow stromal cells of patients with multiple myeloma (MM) produce more proinflammatory cytokines"
26. "A comprehensive program for controlling and monitoring access to thalidomide"